Access to the PPM Journal and newsletters is FREE for clinicians.
Signup for PPM

Addiction Medicine

with Saeed Ahmed, MD and Michael R. Clark, MD, MPH, MBA
Until recently, medication-assisted therapy (MAT), an evidence-based treatment for opioid use disorder (OUD), was restricted to physician prescribing only.
Lofexidine is an alpha-2-adrenergic receptor agonist distributed in the United States by US WorldMeds under license from Britannia Pharmaceuticals Limited (brand name: Lucemyra).
As pain management clinical pharmacists working with an interdisciplinary pain team, it is not uncommon to find patients using and abusing various substances not prescribed to them. What is relatively rare is when a patient reports using a substance of which the team is unfamiliar.
PEMF that activates brainwaves associated with contentment may reduce common opioid withdrawal symptoms.
Basic principles in urine drug monitoring (UDM) are reviewed and applied to a patient testing positive for delta-9-tetrahydrocannabinol (THC) and opiates
Jennifer Schneider MD, PhD, digs into a common—and frustrating—misunderstanding in pain medicine terminology.
With addiction rising, demand for formulations such as buprenorphine (Probuphine) to aid in opioid addiction treatment (MAT) continues to grow.
Critical disparities identified among patient population groups.
A 5-year analyses from Millennium Health showed that patients undergoing drug monitoring, or UDT, as part of chronic opioid therapy, among other reasons, tested positive for a broad range of other unexpected medications. Plus, a look at buprenorphine and gabapentinoid abuse and drug-detection trends.
With a rise in opioid overdoses, the authors look at the growing trend of storing emergency naloxone, such as Evzio or Narcan, in school campuses across the US.
Partial agonists such as buprenorphine may offer an effective opioid alternative for pain management.
Using polymer nanoparticles, researchers are developing a better-acting emergency alternative from naloxone.
ANS-6637 may reduce “surges” without affecting dopamine brain levels.
Improvised devices are typically used as quick-acting options for the untrained.
The buprenorphine and naloxone sublingual film is now available in the US
Inside the pharmacodynamics and presentation of loperamide including potential abuse and related patient behaviors.
Basic principles in urine drug monitoring (UDM) are reviewed and applied to a patient testing positive for oxycodone and amphetamine.
Withdrawal and craving scores for the buprenorphine product remained constant and consistently lower than placebo.
Where the states are exceeding, and what they can do to improve.
Recently FDA-approved, reSET-O encourages CBT guidelines to coincide with opioid use disorder treatment.
Strategies for ordering, understanding, and communicating opioid therapy screening results.
With Lindsey Vuolo, JD, MPH, Paul George, MD, MPHE, Josiah Rich, MD, MPH, and Jeff Gud
FDA makes a motion to increase medication-assisted treatment for opioid addiction.
Gaining clearance from the Food and Drug Administration (FDA), 2 new drug screening tests offer practitioner immediate, in-office results for the 5 most commonly abused opioid-derived drugs and for fentanyl.
President Trump established a new commission to combat opioid addiction, taps Governor Chris Christie to head--Practical Pain Management gets reaction from physicians in the field.
Drug-seeking behaviors may be very similar to those presented in patients with inadequately controlled pain.
New research suggests that deep brain stimulation of the brain (subthalamic nucleus) may reduce heroin abuse in an animal model.
New SAMHSA smartphone app provides doctors instant access to resources for medication assisted treatment (MAT).
Survey finds that many clinicians have negative attitudes about opioid addiction, often blaming the patient. Learn more about the new national survey.
HHS takes steps to stem tide of opioid-related overdose, death, and dependence.
When a clinician orders urine drug testing for a patient prescribed chronic opioid therapy (COT), it is essential that the results are interpreted correctly because they often have significant clinical implications. A positive test result showing drugs and/or metabolites found in urine is easily understood.
Benzodiazepines, which first entered the US pharmaceutical market in the early 1960s, fall under the class of drugs referred to as sedative-hypnotics.1 Benzodiazepines possess anxiolytic, anticonvulsant, hypnotic, sedative, muscle relaxant, and amnesic effects.2 They are generally well-tolerated, safe, and effective for short-term use.
Experts answer the question: Can Butrans be used for opioid addiction?
Chronic pain and addiction are frequent comorbidities, creating a therapeutic dilemma for many pain specialists.
Interpreting urine drug tests in pain patients treated with oxycodone requires an understanding that oxymorphone, although considered a minor metabolite, can sometimes equal or exceed urine concentrations of oxycodone.
close X